Aspirus Health has introduced the TriClip G4 System, the first FDA-approved technology that allows physicians to repair the tricuspid valve without open-heart surgery.
The device, approved by the U.S. Food and Drug Administration on April 4, 2024, offers a groundbreaking, minimally invasive treatment option for patients with tricuspid valve disease, according to an Aspirus Health news release.
The tricuspid valve has long been one of the most difficult heart valves to treat surgically. Traditional surgery carries higher risks, particularly for older adults who often do not respond well to medication alone. The TriClip device provides a lower-risk alternative that helps reduce hospitalizations and improve quality of life.
“This is a tremendous advancement for our patients,” said Dr. Colleen Lane, Aspirus interventional cardiologist. “Many of the people who suffer from tricuspid valve disease are older and may not be good candidates for open-heart surgery. With the TriClip, we can now offer a safe, effective and much less invasive treatment that can significantly improve outcomes.”
Aspirus is among the first health care providers in Wisconsin to make this procedure available. The procedure was successfully performed for the first time at Aspirus this year.
For information, visit aspirus.org.
